CNTX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	19 946.00
Vidutinė apimtis	55 784.00
Rinkos kapitalizacija	22.51M
EPS	$0 ( 2024-03-27 )
Kita pelno data	( $-0.390 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.940
ATR14	$0.0230 (1.63%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Minai-azary Jennifer Lynn	Buy	160 115	Stock Option (right to buy)
2024-03-21	Levit Alex C.	Buy	153 515	Stock Option (right to buy)
2024-03-21	Lehr Martin A.	Buy	291 402	Stock Option (right to buy)
2023-05-31	Kantoff Philip W.	Buy	25 000	Stock Option (right to buy)
2023-05-31	West Linda	Buy	25 000	Stock Option (right to buy)

INSIDER POWER
100.00
Last 72 transactions
Buy: 4 162 098 \| Sell: 2 098 089

Context Therapeutics Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SGH	0.957
KOPN	0.957
PLAB	0.949
ALR	0.941
STER	0.939
ELTK	0.938
MRVL	0.935
XBIT	0.931
EVLO	0.927
CALA	0.927

10 Labiausiai neigiamai susiję koreliacijos
OPTN	-0.919
SBNYP	-0.909
ASO	-0.901
FANH	-0.899
ATHN	-0.896
PHCF	-0.895
CDAK	-0.885
PAYS	-0.885
MTSI	-0.877
AGFS	-0.876

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Context Therapeutics Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-12 044.00 (0.00 %)
EPS:	$-1.500

FY	2023
Pajamos:	$0
Bruto pelnas:	$-12 044.00 (0.00 %)
EPS:	$-1.500

FY	2022
Pajamos:	$0
Bruto pelnas:	$-9 268.00 (0.00 %)
EPS:	$-0.900

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.024

Financial Reports:

No articles found.

Context Therapeutics Inc.

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.